-
Self-delivery (Gymnotic delivery): Uptake of the FANA ASOs without a delivery agent. No formulation, conjugate or viral vector (like AAV) needed for delivery.
-
Ideal for primary cells or difficult to transfect cell lines (no formulation, conjugate or viral vector needed for delivery). Works very well with hard-to-transfect cells especially primary cells which depict true biology (T- cells, B-cells, neuronal cultures and others).
-
FANA Treatment Workflow
-
Ideal for in vivo studies (no formulation, conjugate or viral vector needed for delivery).
-
Can work with fish, insect, and amphibian models (no formulatio or conjugates needed for delivery).
-
Non-toxic and do no cause cell death. No need to grow excessive number of cells (typically there is a need to do grow excessive number of cells when we use transfection agents to compensate for high cell death caused by these toxic reagents).
-
Resistant to degradation by serum and cellular nucleases significantly improves duration of activity. FANA oligos do not degrade (up to several weeks/months)
-
Long term sustained silencing (can be used as an alternative for stable cell lines).
-
Low non-specific protein binding decreases toxicity.
-
Does not alter the biology of cells and the experiment (as in case of transfection and delivery reagents).
-
Ability to bind to RNA target with high affinity and specificity.
-
No RISC associated off target effects (as in case of siRNAs).
-
Effective in low concentrations; high bioavailability.
-
Excellent reproducibility.
-
Saves significant time and resources.
-
Cost effective and efficient.
-
Super easy to use (very convenient protocol).